ok-101
Peptideexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 28, 2023 (NCT05759208)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
CMKLR1 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06637527 | Phase 2 | Oct 15, 2024 | Okyo Pharma Ltd, Tufts University |
| NCT05759208 | Phase 2 | Apr 28, 2023 | Okyo Pharma Ltd, ORA, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Okyo Pharma Ltd | For profit | 2 | 2 | 1 | 2023 |
| ORA, Inc. | For profit | 1 | 0 | 1 | 2023 |
| Tufts University | Academic/Hospital | 1 | 0 | 1 | 2024 |
3 organizations
Page 1 / 1